I, like over 37000 Australians,  have Multiple Sclerosis (MS), a condition that greatly impacts every aspect of my life. Managing MS requires a combination of treatments, and for many like myself, Kesimpta and Ocrevus are an essential part of treating MS.

At the moment, these life-changing medications are available through the Pharmaceutical Benefits Scheme (PBS) in Australia, which makes them accessible and affordable for the thousands who rely on them. MS  cases are increasing by around 4% each year.

However, there is a threat that these essential medications could be removed from the PBS. The impact of this decision would be devastating, as it would make Kesimpta and Ocrevus unaffordable for Australians living with MS.

Most individuals with MS cannot use alternatives like Tysabri due to the risk of activating the dormant John Cunningham Virus, an incurable and potentially fatal side effect.

Ovrevus is the only medication that has been shown to help those with PPMS (Primary Progressive Multiple Sclerosis). PPMS is a type of MS where neurological functions get worse over time from the onset of the disease, without early relapses or remissions. PPMS accounts for 10% to 15% of MS cases.  It's characterised by nerve degeneration, not inflammation, which makes it harder to treat.  Ocrevus is currently the only disease-modifying therapy specifically approved to treat PPMS.

Without access to Kesimpta and Ocrevus, thousands of Australians could suffer severe physical, mental, and financial hardships. People have talked about taking their own lives if this medication is removed from PBS which is heartbreaking to read. 

Multiple Sclerosis is 3 times more common in women than men. Tasmania has the highest rate of MS in the country, with approximately 190 people diagnosed per 100,000.

MS is a chronic illness that requires ongoing and comprehensive treatment, there is no cure. The cost of these MS medications without PBS support could exceed tens of thousands of dollars annually, putting an emotional and financial burden on affected individuals and our families. 

Access to affordable medication is not just a health issue—it's a matter of human equality and human rights. All Australians deserve the right to live their lives with as much normalcy and dignity as possible, and keeping these medications on PBS is a vital part of these rights.

We urge Mark Butler, Minster of Health and Ageing along with others in the Australian Government and PBAC, to reconsider any plans that would remove Kesimpta and Ocrevus from the Pharmaceutical Benefits Scheme. These medications have been life saving for the thousands of people that are on them. 

Let's stand together to protect access to these essential medications for all the MS Warriors who need them.

 Please sign this petition and support those of us who depend on Kesimpta and Ocrevus to maintain our health and quality of life.

Thank you